NeuroDerm Announces Enrollment in a Second Phase 2 Study of ND0612L, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson’s Disease
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson’s disease.